Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 3
2016 1
2019 1
2020 3
2021 5
2022 7
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients.
Jiménez N, Garcia de Herreros M, Reig Ò, Marín-Aguilera M, Aversa C, Ferrer-Mileo L, García-Esteve S, Rodríguez-Carunchio L, Trias I, Font A, Rodriguez-Vida A, Climent MÁ, Cros S, Chirivella I, Domènech M, Figols M, Carles J, Suárez C, Herrero Rivera D, González-Billalabeitia E, Cívico C, Sala-González N, Ruiz de Porras V, Ribal MJ, Prat A, Mellado B. Jiménez N, et al. Among authors: ruiz de porras v. Eur Urol Oncol. 2024 Mar 1:S2588-9311(24)00025-7. doi: 10.1016/j.euo.2023.12.012. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38429210 Free article.
Dual inhibition of MEK and PI3Kβ/δ-a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer.
Ruiz de Porras V, Bernat-Peguera A, Alcon C, Laguia F, Fernández-Saorin M, Jiménez N, Senan-Salinas A, Solé-Blanch C, Feu A, Marín-Aguilera M, Pardo JC, Ochoa-de-Olza M, Montero J, Mellado B, Font A. Ruiz de Porras V, et al. Front Pharmacol. 2024 Jan 22;15:1331648. doi: 10.3389/fphar.2024.1331648. eCollection 2024. Front Pharmacol. 2024. PMID: 38318136 Free PMC article.
Agarose spot migration assay to measure the chemoattractant potential of extracellular vesicles: applications in regenerative medicine and cancer metastasis.
Clos-Sansalvador M, Monguió-Tortajada M, Grau-Leal F, Ruiz de Porras V, Garcia SG, Sanroque-Muñoz M, Font-Morón M, Franquesa M, Borràs FE. Clos-Sansalvador M, et al. Among authors: ruiz de porras v. BMC Biol. 2023 Oct 26;21(1):236. doi: 10.1186/s12915-023-01729-5. BMC Biol. 2023. PMID: 37884994 Free PMC article.
Predictive signature of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer integrating mRNA expression, taxonomic subtypes, and clinicopathological features.
Font A, Domenech M, Ramirez JL, Marqués M, Benítez R, Ruiz de Porras V, Gago JL, Carrato C, Sant F, Lopez H, Castellano D, Malats N, Calle ML, Real FX. Font A, et al. Among authors: ruiz de porras v. Front Oncol. 2023 Aug 3;13:1155244. doi: 10.3389/fonc.2023.1155244. eCollection 2023. Front Oncol. 2023. PMID: 37588099 Free PMC article.
Nomogram based on baseline clinicopathological characteristics for predicting bladder cancer-specific survival to neoadjuvant chemotherapy in muscle-invasive bladder cancer.
Font A, Domenech M, Buisan O, Lopez H, González A, Etxaniz O, Matas M, Elias X, Gomez M, Figols M, Horneros J, Pardo JC, Notario L, Ruiz de Porras V, Perez I, Areal J, Esteve A. Font A, et al. Among authors: ruiz de porras v. World J Urol. 2022 Nov;40(11):2627-2634. doi: 10.1007/s00345-022-04147-4. Epub 2022 Sep 15. World J Urol. 2022. PMID: 36107212
24 results